Publicaciones en las que colabora con Antonio Viudez Berral (15)

2019

  1. Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study)

    British Journal of Cancer, Vol. 121, Núm. 7, pp. 537-544

2018

  1. A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis

    Journal for ImmunoTherapy of Cancer, Vol. 6, Núm. 1

2017

  1. Fecal incontinence and radiation dose on anal sphincter in patients with locally advanced rectal cancer (LARC) treated with preoperative chemoradiotherapy: a retrospective, single-institutional study

    Clinical and Translational Oncology, Vol. 19, Núm. 8, pp. 969-975

  2. Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer

    Gastric Cancer, Vol. 20, Núm. 3, pp. 465-474

2016

  1. Expresión inmunohistoquímica de MGMT (o(6)-metilguanina-DNA-metiltransferasa), NDRG-1 (n-myc downregulated gene-1) y PHLDA-3 (pleckstrin homology-like domain, family a, member 3) y su correlación con el silenciamiento por metilación en pacientes intervenidos de tumores neuroendocrinos de páncreas. Determinación del rol pronóstico de dicha firma inmunohistoquímica y epigenética

    Expresión inmunohistoquímica de MGMT (o(6)-metilguanina-DNA-metiltransferasa), NDRG-1 (n-myc downregulated gene-1) y PHLDA-3 (pleckstrin homology-like domain, family a, member 3) y su correlación con el silenciamiento por metilación en pacientes intervenidos de tumores neuroendocrinos de páncreas. Determinación del rol pronóstico de dicha firma inmunohistoquímica y epigenética

  2. Pancreatic neuroendocrine tumors: Challenges in an underestimated disease

    Critical Reviews in Oncology/Hematology, Vol. 101, pp. 193-206

2011

  1. Morbidity, mortality, and pathological response in patients with gastric cancer preoperatively treated with chemotherapy or chemoradiotherapy

    Journal of Surgical Oncology, Vol. 104, Núm. 2, pp. 124-129

2010

  1. Improving disease control in advanced colorectal cancer: Panitumumab and cetuximab

    Critical Reviews in Oncology/Hematology, Vol. 74, Núm. 3, pp. 193-202

  2. Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): A dose-finding study and pharmacogenomic analysis

    British Journal of Cancer, Vol. 102, Núm. 6, pp. 987-994

2009

  1. Unresectableliver metastases from colorectal cancer and hepatic arterial infusion chemotherapy: How, when and to whom?

    CardioVascular and Interventional Radiology

2008

  1. Liver disease induced by radioembolization of liver tumors: Description and possible risk factors

    Cancer, Vol. 112, Núm. 7, pp. 1538-1546

2007

  1. Combining chemotherapy and targeted therapies in metastatic colorectal cancer

    World Journal of Gastroenterology, Vol. 13, Núm. 44, pp. 5867-5876

  2. Epidermal growth factor receptor inhibitors in colorectal cancer treatment: What's new?

    World Journal of Gastroenterology, Vol. 13, Núm. 44, pp. 5877-5887

  3. Metástasis hepáticas de carcinoma colorrectal: Tratamientos regionales

    Gastroenterologia y Hepatologia Continuada

  4. Phase I and Pharmacokinetic Study of Gemcitabine Administered at Fixed-Dose Rate, Combined with Docetaxel/Melphalan/Carboplatin, with Autologous Hematopoietic Progenitor-Cell Support, in Patients with Advanced Refractory Tumors

    Biology of Blood and Marrow Transplantation, Vol. 13, Núm. 11, pp. 1324-1337